Its total income increased to Rs 24,416 crore from the year-ago's Rs 23,638 crore, while the total expenditure was lower at Rs 15,596 crore as against Rs 16,089 crore
JLR posts its highest free cash flows in Q3
Wholetime director and CEO Rajeev Talwar to step down on March 31
OTC drugs, health supplements and immunity boosting products grow in healthy double digits
The firm on Friday reported over 68 per cent dip in its consolidated net profit
The company has repaid debt of about $490 million in 9MFY21; filings for 90 ANDAs await US FDA approval
Net sales up on higher commodity prices, rupee depreciation, increased volumes at Zinc India and iron ore business
Board declares interim dividend of Rs 7.50 per share
DRL said the Q3 results were impacted primarily due the non-recognition of deferred tax assets on impairment.
Net interest income for the reporting quarter rose 4.85 per cent to Rs 6,590 crore, from Rs 6,285 in Q3FY20.
Other income declined by eight per cent to Rs 1,646 crore in Q3 of FY21 from Rs 1,790 crore in Q3 of FY20.
Direct-to-home arm Dish TV India on Friday reported a consolidated net profit of Rs 86.41 crore for the third quarter ended in December 2020.
Both the benchmarks have erased around 5 per cent during the week
AUM up 16% to Rs 75,813 cr; Net NPA without Supreme Court dispensation at Rs 1,404 cr vs Rs 937.9 cr a year ago
Rising oil prices yielded inventory gains and a rise in petrochemical margins
Battery maker Exide Industries on Friday reported over two-fold jump in consolidated net profit after tax (PAT)
Net interest income of the company grew 57 per cent YoY to Rs 573 crore
The key monitorable, analysts said, will be downgrades to BBB and below list; outlook on asset quality; update on restructuring account; and business outlook
Dr Reddy's Laboratories on Friday reported a consolidated net profit of Rs 20 crore for the October to December quarter as against a consolidated net loss of Rs 570 crore in the year-ago period.Not accounting for impairment cost, the company's net profit in the quarter would have been at Rs 882 crore, it said.The company's consolidated revenues grew 12 per cent year-on-year to Rs 4,930 crore.There were significant changes to the market conditions for certain of the products fanning part of company's global generics and proprietary products segments, said the company."We continued with our growth momentum while maintaining EBITDA margins. We are progressing well on phase three clinical trials for Sputnik V vaccine in India," said Co-Chairman and Managing Director G V Prasad.The company's revenues in India increased by 26 per cent year-on-year to Rs 959 crore in Q3 FY21. In North America, the sales rose 9 per cent to Rs 1,739 crore.
TVS Motor Company on Thursday reported a 84.7 per cent increase in consolidated net profit at Rs 289.69 crore for the third quarter ended December, riding on the back of higher sales